News Releases

09 May '19
Alvotech today announced the appointment of Mark Levick as Chief Executive Officer, effective 5 August 2019. Mark brings over 18 years of global industry experience, with a very impressive track record of value creation and success in bringing new biosimilars to market.
09 Apr '19
Alvotech and Fuji pharma have entered into a binding agreement for the exclusive partnership and supply to commercialize Alvotech’s ustekinumab biosimilar (Stelara®) in Japan.  Alvotech and Fuji Pharma recently announced Fuji´s ~US$50 million investment into Alvotech that further strengthens the
13 Mar '19
Alvotech enrolls first patient in clinical phase III study involving biosimilar version of HUMIRA® Alvotech’s AVT02 is being developed as a biosimilar of the HUMIRA® high-concentration (100mg/mL) product, expected to be more convenient for patients, compared to biosimilar competitors 400
25 Feb '19
Following the late 2018 announcement that Alvotech was to enter into a joint venture with Changchun High & New Technology Industries Group Inc (“CCHN”), representatives from the two companies met up last week to discuss the groundbreaking of the new facility.
22 Jan '19
Fuels growth and biosimilar development in a fast-growing market Alvotech announced today that it has successfully raised US$300 million through a private bond offering. Net proceeds from the capital raised will be used to fuel continued growth, refinance of existing debt and the further
17 Dec '18
Biopharmaceutical company Alvotech announced today that Japan-based Fuji Pharma has acquired a 4.2% stake in the business for approximately US$50 million. Alvotech and Fuji Pharma recently announced an exclusive agreement for development and commercialization of biosimilars in Japan.
19 Nov '18
Alvotech and Fuji Pharma (Tokyo Stock Exchange: 4554) today announce that the two companies are entering into an exclusive partnership for the commercialization by Fuji Pharma of Alvotech’s biosimilar portfolio in Japan. Alvotech gains access to the third largest pharmaceutical market in the world
27 Oct '18
Alvotech today announced it is entering into a joint venture with Changchun High & New Technology Industries Group Inc (“CCHN”) which will enable Alvotech to develop, manufacture and commercialize its biosimilar portfolio in China. A new state-of-the-art biologics facility built in China Alvotech
25 Oct '18
Alvotech is delighted to announce that it has received manufacturing licensure from the Icelandic Medicines Agency, for its biopharmaceutical facility in Reykjavik, Iceland. The 13,000m² facility, located in the science park of the University of Iceland in Reykjavik, is dedicated to the development
Displaying 161 - 170 of 172